EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS • US30063P1057

103.38 USD
+0.13 (+0.13%)
At close: Feb 27, 2026
103.38 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

EXAS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. While EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability. EXAS is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • EXAS had negative earnings in the past year.
  • EXAS had a positive operating cash flow in the past year.
  • EXAS had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -16.72%, EXAS is in the better half of the industry, outperforming 78.31% of the companies in the same industry.
  • EXAS's Return On Equity of -39.44% is fine compared to the rest of the industry. EXAS outperforms 70.63% of its industry peers.
Industry RankSector Rank
ROA -16.72%
ROE -39.44%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • Looking at the Gross Margin, with a value of 67.37%, EXAS belongs to the top of the industry, outperforming 80.81% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EXAS has declined.
  • The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for EXAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • EXAS has an Altman-Z score of 3.02. This indicates that EXAS is financially healthy and has little risk of bankruptcy at the moment.
  • EXAS has a better Altman-Z score (3.02) than 67.37% of its industry peers.
  • EXAS has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as EXAS would need 9.47 years to pay back of all of its debts.
  • EXAS has a better Debt to FCF ratio (9.47) than 90.59% of its industry peers.
  • EXAS has a Debt/Equity ratio of 0.93. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.93, EXAS is doing worse than 74.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF 9.47
Altman-Z 3.02
ROIC/WACCN/A
WACC7.86%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

  • EXAS has a Current Ratio of 2.72. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
  • EXAS has a Current ratio of 2.72. This is in the lower half of the industry: EXAS underperforms 68.52% of its industry peers.
  • EXAS has a Quick Ratio of 2.44. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
  • EXAS's Quick ratio of 2.44 is on the low side compared to the rest of the industry. EXAS is outperformed by 69.48% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.44
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 81.51% over the past year.
EPS 1Y (TTM)81.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.12%

3.2 Future

  • EXAS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.63% yearly.
  • EXAS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.65% yearly.
EPS Next Y132.48%
EPS Next 2Y79.82%
EPS Next 3Y61.45%
EPS Next 5Y44.63%
Revenue Next Year13.54%
Revenue Next 2Y13%
Revenue Next 3Y10.73%
Revenue Next 5Y7.65%

3.3 Evolution

EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 309.00, which means the current valuation is very expensive for EXAS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 87.33% of the companies listed in the same industry.
  • EXAS is valuated expensively when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 309
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200 300

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaply inside the industry as 89.44% of the companies are valued more expensively.
  • EXAS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXAS is cheaper than 92.13% of the companies in the same industry.
Industry RankSector Rank
P/FCF 79.84
EV/EBITDA 329.08
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates EXAS does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as EXAS's earnings are expected to grow with 61.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y79.82%
EPS Next 3Y61.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EXAS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXACT SCIENCES CORP

NASDAQ:EXAS (2/27/2026, 8:00:02 PM)

After market: 103.38 0 (0%)

103.38

+0.13 (+0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13
Earnings (Next)04-29
Inst Owners94.41%
Inst Owner Change-11.19%
Ins Owners0.85%
Ins Owner Change-0.32%
Market Cap19.73B
Revenue(TTM)N/A
Net Income(TTM)-986.58M
Analysts66.9
Price Target105.48 (2.03%)
Short Float %3.56%
Short Ratio2.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.24%
Min EPS beat(2)-40.06%
Max EPS beat(2)94.53%
EPS beat(4)1
Avg EPS beat(4)-344.13%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)4
Avg EPS beat(8)-160.89%
EPS beat(12)8
Avg EPS beat(12)-92.72%
EPS beat(16)11
Avg EPS beat(16)-67.39%
Revenue beat(2)2
Avg Revenue beat(2)2.8%
Min Revenue beat(2)2.65%
Max Revenue beat(2)2.95%
Revenue beat(4)3
Avg Revenue beat(4)1.49%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)2.95%
Revenue beat(8)3
Avg Revenue beat(8)0.13%
Revenue beat(12)6
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)1.59%
PT rev (1m)1.1%
PT rev (3m)22.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5200%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 309
P/S 6.4
P/FCF 79.84
P/OCF 51
P/B 7.89
P/tB N/A
EV/EBITDA 329.08
EPS(TTM)-1.03
EYN/A
EPS(NY)0.33
Fwd EY0.32%
FCF(TTM)1.29
FCFY1.25%
OCF(TTM)2.03
OCFY1.96%
SpS16.15
BVpS13.11
TBVpS-4.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.72%
ROE -39.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.37%
FCFM 8.02%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF 9.47
Debt/EBITDA 36.88
Cap/Depr 63.99%
Cap/Sales 4.53%
Interest Coverage N/A
Cash Conversion 611.3%
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.44
Altman-Z 3.02
F-Score4
WACC7.86%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.86%
EPS Next Y132.48%
EPS Next 2Y79.82%
EPS Next 3Y61.45%
EPS Next 5Y44.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.12%
Revenue Next Year13.54%
Revenue Next 2Y13%
Revenue Next 3Y10.73%
Revenue Next 5Y7.65%
EBIT growth 1Y25.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year324.81%
EBIT Next 3Y83.49%
EBIT Next 5Y52.7%
FCF growth 1Y1146.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y179.09%
OCF growth 3YN/A
OCF growth 5YN/A

EXACT SCIENCES CORP / EXAS FAQ

What is the fundamental rating for EXAS stock?

ChartMill assigns a fundamental rating of 3 / 10 to EXAS.


What is the valuation status of EXACT SCIENCES CORP (EXAS) stock?

ChartMill assigns a valuation rating of 4 / 10 to EXACT SCIENCES CORP (EXAS). This can be considered as Fairly Valued.


How profitable is EXACT SCIENCES CORP (EXAS) stock?

EXACT SCIENCES CORP (EXAS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for EXACT SCIENCES CORP?

The Earnings per Share (EPS) of EXACT SCIENCES CORP (EXAS) is expected to grow by 132.48% in the next year.